Summary of the 2024 report on gastroenterology and digestive endoscopy in China
Open Access
- 17 September 2025
- journal article
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 138 (21) , 2693-2701
Abstract
Background: China has made significant progress in medical accessibility and quality over the past decades, and quality improvements in gastroenterology and digestive endoscopy have been consistent. The study aimed to describe the status quo of gastroenterology and digestive endoscopy in the Chinese mainland based on the data from the National Clinical Improvement System (NCIS) and the Hospital Quality Monitoring System (HQMS). Methods: Data were extracted from the NCIS and the HQMS. Data analysis included general information from the Department of Gastroenterology and Endoscopy centers, management of inpatients and outpatients, and annual volume and quality indicators of digestive endoscopy. Acute pancreatitis, gastrointestinal bleeding, inflammatory bowel disease, and cirrhosis were identified as priority diseases and were subjected to detailed analysis. Results: Data from 4620 and 7074 hospitals were extracted from the NCIS and HQMS, respectively. In 2023, 9.6 gastroenterologists, 6.7 endoscopists, and 37.3 gastroenterology beds per hospital nationwide were observed, achieving 19,252.4 outpatient visits, 1615.2 hospitalizations (97.0 for acute pancreatitis, 146.1 for gastrointestinal bleeding, 40.2 for inflammatory bowel disease, and 111.4 for cirrhosis), and 9432.7 digestive endoscopic procedures per hospital. Overall, the quality of practice improved significantly. The proportion of early cancer among gastrointestinal cancers increased from 11.1% in 2015 to 23.4% in 2023, and the adenoma detection rate during colonoscopy increased from 19.3% in 2019 to 26.9% in 2023. Regarding priority diseases, hospitalizations increased, and 31-day unplanned readmission rates decreased between 2019 and 2023. The median hospitalization costs and median proportion of medication costs decreased for acute pancreatitis, gastrointestinal bleeding, and cirrhosis. However, it increased for inflammatory bowel disease. Conclusion: This report evaluates the status quo and development of gastroenterology and digestive endoscopy in the Chinese mainland, providing guidance for future quality improvements.Keywords
This publication has 28 references indexed in Scilit:
- Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2024Gastroenterology, 2025
- Quality indicators for colonoscopyGastrointestinal Endoscopy, 2024
- Global Burden of Digestive Diseases: A Systematic Analysis of the Global Burden of Diseases Study, 1990 to 2019Gastroenterology, 2023
- Continuous monitoring of colonoscopy performance in the Netherlands: first results of a nationwide registryEndoscopy, 2021
- Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based studyThe Lancet Gastroenterology & Hepatology, 2020
- Impact of a Citywide Benchmarking Intervention on Colonoscopy Quality PerformanceDigestive Diseases and Sciences, 2020
- Achieving best outcomes for patients with cardiovascular disease in China by enhancing the quality of medical care and establishing a learning health-care systemThe Lancet, 2015
- Quality Indicators for ColonoscopyAmerican Journal of Gastroenterology, 2015
- Quality indicators for ERCPGastrointestinal Endoscopy, 2015
- Variation of quality of colonoscopy in Italy over five years: A nation-wide observational studyDigestive and Liver Disease, 2013